Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-14
2011-06-14
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254100, C514S254110, C514S255010, C514S254020, C514S254050, C514S254090, C544S360000, C544S366000, C544S369000, C544S371000, C544S373000, C544S375000, C544S376000, C544S379000, C544S390000, C546S194000, C546S196000, C546S213000, C546S214000, C546S222000, C548S525000, C548S556000
Reexamination Certificate
active
07960385
ABSTRACT:
The invention provides compounds of formula I:or a pharmaceutically acceptable salt thereof, wherein R1-3, R5-7, a, X, Y, Y′, Y″, and Z are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.
REFERENCES:
patent: 3732247 (1973-05-01), Helsley et al.
patent: 5070087 (1991-12-01), Teng et al.
patent: 6140333 (2000-10-01), Tsuchiya et al.
patent: 6693202 (2004-02-01), Aggen et al.
patent: 6846835 (2005-01-01), Ogino et al.
patent: 7122558 (2006-10-01), Prat Quinones et al.
patent: 7192978 (2007-03-01), Quinones et al.
patent: 2003/0055080 (2003-03-01), Forner et al.
patent: 2006/0287362 (2006-12-01), Collingwood et al.
patent: 2007/0060563 (2007-03-01), Collingwood et al.
patent: 2008/0207736 (2008-08-01), Ji et al.
patent: 0 309 424 (1989-03-01), None
patent: 0309422 (1989-03-01), None
patent: 0930298 (1999-07-01), None
patent: 1302458 (2003-04-01), None
patent: WO 01/42212 (2001-06-01), None
patent: 03087096 (2003-10-01), None
patent: 2004/056767 (2004-07-01), None
patent: WO 2005/090342 (2005-09-01), None
patent: 2006005980 (2006-01-01), None
patent: WO 2006/048225 (2006-05-01), None
patent: WO 2006/066928 (2006-06-01), None
patent: WO 2006/066929 (2006-06-01), None
patent: WO 2007/017669 (2007-02-01), None
patent: WO 2007/017670 (2007-02-01), None
Copending U.S. Appl. No. 12/333,628, Ji et al. (unpublished).
Biel et al., Central Stimulants II, 26:4096-4103 (1961).
International Search Report for PCT/US2008/010431.
U.S. Appl. No. 12/148,887, Husfeld et al.
Ogino et al., “Muscarinic M3 Receptor Antagonists with (2R)-2-[(1R)-3,3-Difluorocyclopentyl] . . . ”, Bioorganic & Medicinal Chemistry Letters, 13(13): 2167-2172 (2003).
Mitsuya et al., “A Potent, long-acting, orally active (2R)-2-[(1R)-3,3-difluorocyclopenty1]-2-hydroxy-2-phenylacetamide: A novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors”, Journal of Medicinal Chemistry, 2000, 43(26), pp. 5017-5029.
Husfeld Craig
Ji Yu-Hua
Lee Rick
Li Li
Mu YongQi
Bernhardt Emily
Eberle Shelley
Hagenah Jeffrey A.
Theravance Inc.
LandOfFree
Guanidine-containing compounds useful as muscarinic receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Guanidine-containing compounds useful as muscarinic receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Guanidine-containing compounds useful as muscarinic receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2724342